





Stock Code: 002422

## **Kelun Pharmaceuticals**

- □ Founded in 1996, with over 100 subsidiaries worldwide
- Kelun Pharmaceuticals is a publicly traded company (Shenzhen, stock code: 002422)
- Among the top 10 Chinese pharmaceutical companies with a revenue exceeding 6 billion USD in 2018

## **Kelun Pharmaceutical Research Institute**

- Over 2,000 R&D scientists, headquartered in Chengdu, China with satellite research centers in Tianjin, Suzhou, and New Jersey
- Programs include innovative small molecules and biologics, generics, and new drug delivery systems
- Focusing on cancer, diabetes, liver diseases, CNS, cardiovascular and autoimmune diseases, etc.

## **Kelun-Biotech Biopharmaceutical Co.**

- A subsidiary of Kelun Pharmaceuticals established in 2016, focusing on innovative small molecules and biologics
- pipeline with 45 innovative small-molecule drug programs and 40 biological programs, including mAb, bispecific Ab, ADC, etc.

## **KLUS Pharma (Kelun US)**

- A subsidiary of Kelun Pharmaceuticals and founded in 2016. Based in Cranbury, NJ
- Three functional divisions: R&D, clinical research, and business development
- □ Focuses on biologics drug discovery & development

Biologics	Location	Clinical	Location
Vice President, Biologics R&D	Chengdu, China	Director, Medical Science	Chengdu & Shanghai, China
Vice President, Biologics Manufacturing	Chengdu, China	Discrete Data Management	22
Vice President, Quality	Chengdu, China	Director, Data Management	Chengdu, China
Director, Drug Discovery-Phage Display & Bispecific Ab	Chengdu, China	Director, Project Management	Chengdu, China
		Director, Biostatistics	Chengdu, China
Director, Process-Cell Culture/Purification/Formulation	Chengdu, China	Director, Statistical Programming	Chengdu, China
Director, Cell Therapy R&D	Chengdu, China	Director, Pharmacovigilance	Chengdu & Shanghai, China
Director, Oncolytic Virus R&D	Chengdu, China	Director, Registration and Medical Writing	Chengdu, China
Director, Biologics Quality Assurance	Chengdu, China	Director, Pharmacology	Chengdu, China
Director, Cell Therapy Manufacturing (QC/QA)	Chengdu, China	Director, Operation	Chengdu, China
Director, Regulatory Affairs	Chengdu, China	Director, Operational Quality Control	Chengdu, China
Director, Antibody Engineering	New Jersey, US	Director, Database Design	Chengdu, China
Director, Bioassay	New Jersey, US	Generic Drugs	Location
Director, BD	New Jersey, US	Vice President, Generic Drugs R&D	Chengdu, China
Innovative Small Molecule	Location	Vice President, Formulation - Oral Dosage	Chengdu, China
Vice President, Small Molecules R&D	Chengdu, China	Vice President, Formulation - Injectables	Chengdu, China
Director, Medicinal Chemistry	Chengdu & Suzhou, China New Jersey, US	VP, NDDS	Chengdu, China
		Vice President, Branch-Tianjin or Suzhou	Tianjin & Suzhou, China
Director, Computational Chemistry	Chengdu & Suzhou, China New Jersey, US	Director, IV- Powder and Liquid Dual-Chamber Bag	Chengdu, China
Discotor Torrigales	<b>,</b>	Director, Crystallization Process	Chengdu, China
Director, Toxicology	Chengdu, China	Director, IV Packaging	Chengdu, China
Director, Bioanalytics	Chengdu, China	Director, IV Lipid	Chengdu, China
Director, Innovative Process	Chengdu, China	Director, Peptide Process and Purification	Chengdu, China
		•	-